Key Points Eli Lilly's breakthroughs in its core therapeutic area are driving excellent financial results. The company could hit significant headwinds if it encounters clinical setbacks and ceases to innovate. However, Eli Lilly's pipeline appears deep enough to generate additional billion-dollar products across multiple areas. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been on a historic run over the past five years, outperforming similarly sized peers in the pharmaceutical industry and becoming the first healthcare stock to reach a $1 trillion market cap. The company's diabetes and weight-loss portfolio has been the main engine behind its terrific performance of late, and it remains strong.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.